ID: ALA1950173

Max Phase: Preclinical

Molecular Formula: C14H17ClN2O4

Molecular Weight: 312.75

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCOC(=O)/C(CCCC(=O)O)=N\Nc1ccc(Cl)cc1

Standard InChI:  InChI=1S/C14H17ClN2O4/c1-2-21-14(20)12(4-3-5-13(18)19)17-16-11-8-6-10(15)7-9-11/h6-9,16H,2-5H2,1H3,(H,18,19)/b17-12-

Standard InChI Key:  BEDHFABVWCBYFR-ATVHPVEESA-N

Associated Targets(Human)

Kynurenine--oxoglutarate transaminase I 96 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 312.75Molecular Weight (Monoisotopic): 312.0877AlogP: 2.93#Rotatable Bonds: 8
Polar Surface Area: 87.99Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.07CX Basic pKa: CX LogP: 3.79CX LogD: -0.26
Aromatic Rings: 1Heavy Atoms: 21QED Weighted: 0.44Np Likeness Score: -0.54

References

1. Akladios FN, Nadvi NA, Park J, Hanrahan JR, Kapoor V, Gorrell MD, Church WB..  (2012)  Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I.,  22  (4): [PMID:22281190] [10.1016/j.bmcl.2011.12.138]

Source